Ginkgo Bioworks (DNA) Q4 Revenue Tops Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2021 Financial Results
March 28, 2022 4:01 PM EDT$314 million of Total revenue in 2021, representing an increase of 309% over 2020
31 new Cell Programs added in 2021, representing 72% growth over 2020
Over $1.5 billion cash balance, providing meaningful multi-year runway as we drive towards profitability
BOSTON, March 28, 2022 /PRNewswire/ --Â Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), the leading horizontal platform for cell programming, today announced its results for the fourth quarter and year ended December 31, 2021. The update, including a webcast slide presentation with additional details on the fourth quarter and supplemental financial information, will be available at... More
